News & Videos - MEDIVIR AB [CBOE]

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024 PR Newswire HUDDINGE, Sweden, May 30, 2024 HUDDINGE, Sweden , May 30, 2024 /PRNewswire/ -- In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) ("Medivir") on 7 May 2024 ("LTIP 2024"), it is today announced that the board of directors of Medivir has resolved on (i) a share issue of 1,700,000 shares of series C, (ii) repurchase of the 1,700,000...

Medivir to present at Redeye Growth Day PR Newswire STOCKHOLM, May 30, 2024 STOCKHOLM , May 30, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at Redeye Growth Day, today May 30, 2024 . CEO Jens Lindberg will present updated data from the ongoing phase 1b /2a clinical study with fostroxacitabine bralpamide (fostrox)...

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program PR Newswire STOCKHOLM, May 23, 2024 STOCKHOLM , May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is...

Resolutions at the Annual General Meeting in Medivir on 7 May 2024 PR Newswire STOCKHOLM, May 7, 2024 STOCKHOLM , May 7, 2024 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual general meeting today on 7 May 2024 . The annual general meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The annual general meeting in Medivir Aktiebolag (publ) resolved the following: Approval of profit...

MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024 PR Newswire STOCKHOLM, April 30, 2024 STOCKHOLM , April 30, 2024 /PRNewswire/ -- Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January – March Financial summary for the quarter Net turnover amounted to SEK 0.5 (0.4) million. The loss before interest, tax, depreciation...

Medivir brings the Q1 webcast forward to 10 a.m. on April 30 PR Newswire STOCKHOLM, April 29, 2024 STOCKHOLM , April 29, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30 , at 10 a.m. CET . The webcast is brought forward as Nasdaq Stockholm closes earlier. For additional...

Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI PR Newswire STOCKHOLM, April 29, 2024 STOCKHOLM , April 29, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in hepatocellular carcinoma (HCC) has been accepted for presentation at...

FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease PR Newswire STOCKHOLM, April 25, 2024 STOCKHOLM , April 25, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR ) (STO: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease Designation...

Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue PR Newswire STOCKHOLM, April 23, 2024 STOCKHOLM , April 23, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global phase 2b study...

Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701 PR Newswire STOCKHOLM, April 15, 2024 STOCKHOLM , April 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a...

Medivir to present at Investing in Oncology Forum on April 10 PR Newswire STOCKHOLM, April 9, 2024 STOCKHOLM , April 9, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Investing in Oncology Forum on April 10, 2024 . CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b /2a clinical study...

Medivir 2023 Annual Report published PR Newswire STOCKHOLM, April 4, 2024 STOCKHOLM , April 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the company's website: www.medivir.com . In the fall of 2023, very promising data from the ongoing phase 1b /2a study with Medivir's spearhead project fostrox in combination with Lenvima ® were presented. The combination has shown continued improved clinical benefit in patients...

Notice of Annual General Meeting of Medivir AB (publ) PR Newswire STOCKHOLM, April 4, 2024 STOCKHOLM , April 4, 2024 /PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm , are hereby summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 CEST at Helio GT30, Grev Turegatan 30, Stockholm, Sweden . Shareholders can participate in the annual general meeting by attending the venue in person or by voting in...

Medivir to present at Swiss Nordic Bio in Zürich on March 7 PR Newswire STOCKHOLM, March 6, 2024 STOCKHOLM , March 6, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024 . CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b /2a clinical study with...

Medivir to present at the Life Science Day in Gothenburg on March 6 PR Newswire STOCKHOLM, March 4, 2024 STOCKHOLM , March 4, 2024 /PRNewswire/ -- Medivir AB (NASDAQ STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Life Science Day in Gothenburg on March 6, 2024 . CEO Jens Lindberg will present Medivir with focus on data from the ongoing Phase 1b /2a clinical...

Change in Medivir's nomination committee before the 2024 AGM PR Newswire STOCKHOLM, Feb. 26, 2024 STOCKHOLM , Feb. 26, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm : MVIR) today announces that that the nomination committee before the annual general meeting in May 2024 changes as follows. Anders Hallberg is leaving the nomination committee and HealthInvest Partners has declined new representation in the nomination committee. Other major owners have been asked in order of size and CA...

Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit PR Newswire STOCKHOLM, Feb. 22, 2024 STOCKHOLM , Feb. 22, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical pharmacokinetic (PK) data on dose linearity and systemic exposure from the first study with fostroxacitabine...

MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2023 PR Newswire STOCKHOLM, Feb. 15, 2024 STOCKHOLM , Feb. 15, 2024 /PRNewswire/ -- "The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6 months" October – December Financial summary for the quarter Net turnover amounted to SEK 4.4 (2.3) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -20.1 (-17.9) million. Basic...

Number of shares and votes in Medivir AB on 31 January 2024 PR Newswire STOCKHOLM, Jan. 31, 2024 STOCKHOLM , Jan. 31, 2024 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024 . Both issues have been previously announced through separate...

Medivir announces the outcome of the directed share issue which was announced on 22 January 2024 PR Newswire STOCKHOLM, Jan. 26, 2024 STOCKHOLM , Jan. 26, 2024 /PRNewswire/ -- 7,547,170 shares were issued, and all shares have been subscribed for by and allotted to Hallberg Management AB in accordance with the resolution regarding the share issue. The subscription price was SEK 2.65 which means that Medivir receives issue proceeds of approximately SEK 20 million before deductions of costs related...